The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Targeting Glucose Metabolism to Overcome Resistance to Anticancer Chemotherapy in Breast Cancer
Open accessAbstract
Breast cancer (BC) is the most prevalent cancer in women. BC is heterogeneous, with distinct phenotypical and morphological characteristics. These are based on their gene expression profiles, which divide BC into different subtypes, among which the triple-negative breast cancer (TNBC) subtype is the most aggressive one. The growing interest in tumor metabolism emphasizes the role of altered glucose metabolism in driving cancer progression, response to cancer treatment, and its distinct role in therapy resistance. Alterations in glucose metabolism are characterized by increased uptake of glucose, hyperactivated glycolysis, decreased oxidative phosphorylation (OXPHOS) component, and the accumulation of lactate. These deviations are attributed to the upregulation of key glycolytic enzymes and transporters of the glucose metabolic pathway. Key glycolytic enzymes such as hexokinase, lactate dehydrogenase, and enolase are upregulated, thereby conferring resistance towards drugs such as cisplatin, paclitaxel, tamoxifen, and doxorubicin. Besides, drug efflux and detoxification are two energy-dependent mechanisms contributing to resistance. The emergence of resistance to chemotherapy can occur at an early or later stage of the treatment, thus limiting the success and outcome of the therapy. Therefore, understanding the aberrant glucose metabolism in tumors and its link in conferring therapy resistance is essential. Using combinatory treatment with metabolic inhibitors, for example, 2-deoxy-D-glucose (2-DG) and metformin, showed promising results in countering therapy resistance. Newer drug designs such as drugs conjugated to sugars or peptides that utilize the enhanced expression of tumor cell glucose transporters offer selective and efficient drug delivery to cancer cells with less toxicity to healthy cells. Last but not least, naturally occurring compounds of plants defined as phytochemicals manifest a promising approach for the eradication of cancer cells via suppression of essential enzymes or other compartments associated with glycolysis. Their benefits for human health open new opportunities in therapeutic intervention, either alone or in combination with chemotherapeutic drugs. Importantly, phytochemicals as efficacious instruments of anticancer therapy can suppress events leading to chemoresistance of cancer cells. Here, we review the current knowledge of altered glucose metabolism in contributing to resistance to classical anticancer drugs in BC treatment and various ways to target the aberrant metabolism that will serve as a promising strategy for chemosensitizing tumors and overcoming resistance in BC.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R. L., Torre, L. A., & Jemal, A. (2018) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21492 · Cited by 84,109
Cisplatin: mode of cytotoxic action and molecular basis of resistance
Siddik, Z. H. (2003) · Oncogene · doi:10.1038/sj.onc.1206933 · Cited by 3,335 · cited 1×
“Additionally, an attenuation of Ras and MAPK pathway also mediates cisplatin resistance [178].”
BackgroundThe M2 splice isoform of pyruvate kinase is important for cancer metabolism and tumour growth
Christofk, H. R., Vander Heiden, M. G., Harris, M. H., Ramanathan, A., Gerszten, R. E., Wei, R., Fleming, M. D., Schreiber, S. L., & Cantley, L. C. (2008) · Nature · doi:10.1038/nature06734 · Cited by 2,820
The PI3K–AKT network at the interface of oncogenic signalling and cancer metabolism
Hoxhaj, G., & Manning, B. D. (2020) · Nature Reviews Cancer · doi:10.1038/s41568-019-0216-7 · Cited by 2,137
Florea, A.-M., & Büsselberg, D. (2011) · Cancers · doi:10.3390/cancers3011351 · Cited by 1,759
Self-citationHypoxia, HIF1 and glucose metabolism in the solid tumour
Denko, N. C. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2468 · Cited by 1,707
Gottlob, K., Majewski, N., Kennedy, S., Kandel, E., Robey, R. B., & Hay, N. (2001) · Genes & Development · doi:10.1101/gad.889901 · Cited by 961
Localization of the primary metabolic block produced by 2-deoxyglucose
Wick, A. N., Drury, D. R., Nakada, H. I., Wolfe, J. B., Britton, B., & Grabowski, R. (1957) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)64988-9 · Cited by 780 · cited 1×
“2-Deoxy-D-glucose (2-DG), a glucose analog, competes with glucose for GLUT transporters [90].”
BackgroundRaez, L. E., Papadopoulos, K., Ricart, A. D., Chiorean, E. G., DiPaola, R. S., Stein, M. N., Rocha Lima, C. M., Schlesselman, J. J., Tolba, K., Langmuir, V. K., et al. (2013) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-012-2045-1 · Cited by 543
Glucose Conjugation for the Specific Targeting and Treatment of Cancer
Calvaresi, E. C., & Hergenrother, P. J. (2013) · Chemical Science · doi:10.1039/c3sc22205e · Cited by 398
Cited by
Dong, S., Liang, S., Cheng, Z., Zhang, X., Luo, L., Li, L., Zhang, W., Li, S., Xu, Q., Zhong, M., et al. (2022) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-021-02229-6 · Cited by 458
Unveiling the mechanisms and challenges of cancer drug resistance
Khan, S. U., Fatima, K., Aisha, S., & Malik, F. (2024) · Cell Communication and Signaling · doi:10.1186/s12964-023-01302-1 · Cited by 417
Taxanes in cancer treatment: Activity, chemoresistance and its overcoming
Mosca, L., Ilari, A., Fazi, F., Assaraf, Y. G., & Colotti, G. (2021) · Drug Resistance Updates · doi:10.1016/j.drup.2020.100742 · Cited by 385
Doxorubicin and other anthracyclines in cancers: Activity, chemoresistance and its overcoming
Mattioli, R., Ilari, A., Colotti, B., Mosca, L., Fazi, F., & Colotti, G. (2023) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2023.101205 · Cited by 294
Dai, Y., Sun, Z., Zhao, H., Qi, D., Li, X., Gao, D., Li, M., Fan, Q., Shen, Q., & Huang, W. (2021) · Biomaterials · doi:10.1016/j.biomaterials.2021.120935 · Cited by 117
Metadata
- Authors
- Varghese, E., Samuel, S. M., Líšková, A., Samec, M., Kubatka, P., & Büsselberg, D.
- Venue
- Cancers
- Publisher
- MDPI AG
- Published
- 2020-08-12
- Volume
- 12
- Issue
- 8
- Pages
- 2252
- ISSN
- 2072-6694 (ISSN-L)
- OpenAlex
- W3048584869
- Cited by
- 208
- References
- 17
- FWCI
- 8.41
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Targeting Glucose Metabolism to Overcome Resistance to Anticancer Chemotherapy in Breast Cancer. https://app.cochat.ai/papers/10.3390/cancers12082252
- The paper
- Varghese, E., Samuel, S. M., Líšková, A., Samec, M., Kubatka, P., & Büsselberg, D. (2020). Targeting Glucose Metabolism to Overcome Resistance to Anticancer Chemotherapy in Breast Cancer. Cancers. https://doi.org/10.3390/cancers12082252
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.